Overview of albaconazole

European Infectious Disease

Volumn 5, Issue 2, 2011, Pages 088-91

  Bartroli, Javier ^a   Merlos, Manuel ^a   Sisniega, Heidi ^a  

^a Palau Pharma SA   (Spain)

Author keywords

Albaconazole; Antifungal agents; Chagas' disease; Invasive fungal infections; Onychomycosis; Phase 2; Triazoles; Vulvovaginal candidiasis

Indexed keywords

EID: 84857583704     PISSN: 17551137     EISSN: 17551145     Source Type: Journal    
DOI: None     Document Type: Article

References (45)

1. Sable CA, Strohmaier KM, Chodakewitz JA, Advances in antifungal therapy, Ann Rev Med, 2008;59:361-79.
2. Aperis G, Mylonakis E, Newer triazole antifungal agents: pharmacology, spectrum, clinical efficacy and limitations, Expert Opin Investig Drugs, 2006;15:572-602.
3. Bartroli J, Turmo E, Algueró M, et al., New azole antifungals.
4. Internal data.
5. Ramos G, Cuenca-Estrella M, Monzón A, et al., In vitro comparative activity of UR-9825, fluconazole (FLZ) and itraconazole (ITR) against clinical isolates of Candida spp, J Antimicrob Chemother, 1999;44:283-6.
6. Garau M, Pereiro M Jr, del Palacio A, In vitro susceptibilities of Malassezia species to a new triazole, Albaconazole (UR-9825), and other antifungal compounds, Antimic Agents Chemother, 2003;47:2342-4.
7. Alves SH, Da Matta DA, Azevedo AC, et al., In vitro activities of new and conventional antimycotics against fluconazole-susceptible and non-susceptible brazilian Candida spp isolates, Mycoses, 49:220-5.
8. Arechavala AI, Bianchi MH, Robles AM, et al., Identificación y sensibilidad frente a fluconazol y albaconazol de 100 cepas de levaduras aisladas de flujo vaginal, Rev Iberoam Micol, 2007;24:305-8.
9. Miller JL, Schell WA, Wills EA, et al., In vitro and in vivo efficacies of the new triazole Albaconazole against Cryptococcus neoformans, Antimicrob Agents Chemother, 2005;48:384-7.
10. Morera Y, Torres Rodriguez JM, Jimenez T, et al., Antifungal susceptibilities of 113 clinical isolates of Cryptococcus neoformans and Candida spp. to the new antifungal albaconazole (UR-9825) respect to voriconazole and fluconazole, Trends Med Mycol, 2003;143-7.
11. Trilles L, Fernández-Torres B, Lazéra Mdos S, et al., In vitro antifungal susceptibility of Cryptococcus gattii, J Clin Microbiol, 2004;42:4815-7.
12. Morera-Lopez, Y, Torres-Rodríguez JM, Jiménez-Cabello T, et al., Cryptococcus gattii: in vitro susceptibility to the new antifungal albaconazole versus fluconazole and voriconazole, Med Mycol, 2005;43:505-10.
13. Serena C, Pastor FJ, Ortoneda M, et al., In vitro antifungal susceptibilities of uncommon basidiomycetous yeasts, Antimicrob Agents Chemother, 2004;48:2724-6.
14. Capilla J, Ortoneda M, Pastor FJ, et al., In vitro antifungal activities of the new triazole UR-9825 against clinically important filamentous fungi, Antimicrob Agents Chemother, 2001;45:2635-7.
15. Verweij PE, Nationwide survey of in vitro activity of antifungal agents against clinical Aspergillus fumigatus isolates cultured between 1945 and 1988 in The Netherlands, Presented at: the 38th ICAAC, San Diego, Abstract J-33, 460, 24-27 September 1998.
16. Gené J, Azón-Masoliver A, Guarro J, et al., Cutaneous infection caused by Aspergillus ustus, an emerging opportunistic fungus in immunocompromissed patients, J Clin Microbiol, 2001;39:1134-6.
17. García-Martos P, Guarro J, Gené J, et al., Onychomycosis caused by Aspergillus sclerotiorum, J Mycol Med, 2001;11:222-4.
18. Meletiadis J, Meis JF, de Hoog GS, et al., In vitro susceptibilities of 11 clinical isolates of Exophiala species to six antifungal drugss, Mycoses, 2000;43:309-12.
19. Meletiadis J, Meis J, Rijs A, et al., In vitro susceptibility of 64 clinical Scedosporium prolificans and Scedosporium apiospermum isolates of antifungal agents, Mycoses, 1999;42:144-5.
20. Meletiadis J, Meis JF, Mouton JW, et al., In vitro activities of new and conventional antifungal agents against clinical Scedosporium isolates, Antimicrob Agents Chemother, 2002;46:62-8.
21. Carrillo AJ, Guarro J, et al., In vitro activities of four novel triazoles against Scedosporium spp, Antimicrob Agents Chemother, 2001;45:2151-3.
22. Serena C, Ortoneda M, Capilla J, et al, In vitro activities of new antifungal agents against Chaetomium spp and inoculum standardization, Antimicrob Agents Chemother, 2003;47:3161-4.
23. Fernandez-Torres B, Carrillo AJ, Martín E, et al., In vitro activities of 10 antifungal drugs against 508 dermatophyte strains, Antimicrob Agents Chemother, 2001;45:2524-8.
24. Ortoneda M, Capilla J, Javier Pastor F, et al., In vitro interactions of licensed and novel antifungal drugs against Fusarium spp, Diagn Microbiol Infect Dis, 2004;48:69-71.
25. Azor M, Gené J, Cano J, et al., Universal in vitro antifungal resistance of genetic clades of the Fusarium solani species complex, Antimicrob Agents Chemother, 2007;51:1500-3.
26. Azor M, Gené J, Cano J, et al., In vitro antifungal susceptibility and molecular characterization of clinical isolates of Fusarium verticilloides (F. moniliforme) and Fusarium thapsinum, Antimicrob Agents Chemother, 2008;52:2228-31.
27. Ortoneda M, Capilla J, Pastor FJ, et al., In vitro interactions of approved and novel drugs against Paecilomyces spp., Antimicrob Agents Chemother, 2004;48:2727-9.
28. Trilles L, Fernández-Torres B, Dos Santos Lazéra M, et al., In vitro antifungal susceptibilities of Sporothrix schenckii in two growth phases, Antimicrob Agents Chemother, 2005;49:3952-4.
29. Marimon R, Serena C, Gené J, et al., In vitro antifungal susceptibilities of five species of Sporothrix, Antimicrob Agents Chemother, 2008;52:732-4.
30. Marimon R, Gené J, Cano J, et al., Sporothrix luriei: a rare fungus from clinical origin, Med Mycol, 2008;46:621-5.
31. Gilgado F, Serena C, Cano J, et al., Antifungal susceptibilities of the species of the Pseudallescheria boydii complex, Antimicrob Agents Chemother, 2006;50:4211-3.
32. Urbina J, Lira R, Visbal J, Bartroli, J, In vitro antiproliferative effects and mechanisms of action of the triazole derivative UR-9825 against the protozoan parasite Trypanosoma (Schizotrypanum) cruzi, Antimicr Agents Chemother, 2000;44:2498-502.
33. Urbina J, Lira R, Visbal G, et al., Sterol biosynthesis inhibitors for Chagas' disease, Curr Opin Anti Infect Invest Drugs, 2000;2:40-6.
34. Urbina J, Specific treatment of Chagas' disease: current status and new developments, Curr Opin Anti Infect Invest Drugs, 2001;14:733-41.
35. González GM, Robledo E, Garza-González E, et al., Efficacy of albaconazole against Candida albicans in vaginitis model, Antimicrob Agents Chemother, 2009;53:4540-1.
36. Algueró M, In vitro and in vivo activity of albaconazole, Presented at: Focus Fungal Infect, Abstract 1194, Maui, 19-21 March 2003.
37. Capilla J, Yustes C, Mayayo E, et al., Efficacy of albaconazole in the treatment of disseminated infection by Scedosporium prolificans in rabbits, Antimicr Agents Chemother, 2003;47:1948-51.
38. Guedes PMM, Urbina JA, de Lana M, et al., Activity of the new triazole derivative albaconazole against Trypanosome (schizotrypanum) cruzi in dog hosts, Antimicr Agents Chemother, 2004;48:4286-92.
39. Conte L, UR-9825, a novel, broad spectrum triazole for the treatment of fungal infections: pharmacokinetic study in animals, Abstract P-91, Presented at: Trends in Invasive Fungal Infections 4, 139, Barcelona, 5-8 November 1997.
40. De la Cruz G, Safety and preliminary pharmacokinetics of an oral solution containing albaconazole after single and multiple dose administration to healthy volunteers, Presented at: Focus on Fungal Infections 13, Abstract 1193, Maui, 19-21 March 2003.
41. Corcoran G, Effect of food on the absorption of albaconazole from 50 mg capsules in healthy volunteers, Presented at:21st World Congress on Dermatology, Abstract 6729, Buenos Aires, 30 September - 5 Octoberr 2007.
42. Nadal T, In vitro and in vivo human metabolism of albaconazole, Presented at: Focus on Fungal Infections 13, Abstract 1192, 19-21 March 2003, Maui.
43. De la Cruz G, et al. Lack of QTc effects of albaconazole, a new triazole antifungal, Presented at: Focus on Fungal Infections 13, Abstract 1191, Maui, 19-21 March 2003.
44. Internal data.
45. Bartroli J, A clinical multicenter study comparing efficacy and tolerability between five single oral doses of albaconazole and fluconazole 150 mg single dose in acute vulvovaginal candidiasis, Abstract M-722, Presented at: 45th ICAAC, Washington, 16-19 December 2005.